Meeting
2013 ASCO Annual Meeting
Prediction of early and late distant recurrence in early-stage breast cancer with Breast Cancer Index.
Authors
Yi Zhang
bioTheranostics, Inc., San Diego, CA
Yi Zhang , Catherine A. Schnabel , Brock Schroeder , Piiha-Lotta Jerevall , Rachel Catherine Jankowitz , Olle Stal , Adam Brufsky , Dennis Sgroi , Mark G. Erlander
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 31, 2013 (suppl; abstr 594)
DOI
10.1200/jco.2013.31.15_suppl.594
Abstract #
594
Poster Bd #
8A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer.
First Author: Ciara Marie Kelly
Poster
2023 ASCO Annual Meeting
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, Influence, CTS-5)? A TEAM Pathology substudy.
First Author: Ana-Alicia Beltran-Bless
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2020 ASCO Virtual Scientific Program
Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers.
First Author: Julia Foldi